Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies.
Journal: Infectious diseases and therapy
Published: February 25, 2026
Prevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA®) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial.
Journal: Therapeutic advances in gastroenterology
Published: October 10, 2025
Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial.
Journal: Therapeutic advances in gastroenterology
Published: March 31, 2025
PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: May 20, 2024
Crohn's pericarditis identified with point-of-care ultrasonography: A case report.
Journal: Journal of clinical ultrasound : JCU
Published: May 20, 2020
Showing 1-5 of 5
Last Updated: 09/26/2026